| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 917 | 2022 |
| Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro C Yu, Y Hu, J Duan, W Yuan, C Wang, H Xu, XD Yang PloS one 6 (9), e24077, 2011 | 207 | 2011 |
| Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial LG Bekker, Z Moodie, N Grunenberg, F Laher, GD Tomaras, KW Cohen, ... The lancet HIV 5 (7), e366-e378, 2018 | 112 | 2018 |
| Immune correlates analysis of the ENSEMBLE single Ad26. COV2. S dose vaccine efficacy clinical trial Y Fong, AB McDermott, D Benkeser, S Roels, DJ Stieh, A Vandebosch, ... Nature Microbiology 7 (12), 1996-2010, 2022 | 56 | 2022 |
| Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial Y Fong, Y Huang, D Benkeser, LN Carpp, G Áñez, W Woo, A McGarry, ... Nature communications 14 (1), 331, 2023 | 50 | 2023 |
| Modification of the association between T-cell immune responses and human immunodeficiency virus type 1 infection risk by vaccine-induced antibody responses in the HVTN 505 trial Y Fong, X Shen, VC Ashley, A Deal, KE Seaton, C Yu, SP Grant, G Ferrari, ... The Journal of infectious diseases 217 (8), 1280-1288, 2018 | 40 | 2018 |
| Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC … F Laher, Z Moodie, KW Cohen, N Grunenberg, LG Bekker, M Allen, ... PLoS medicine 17 (2), e1003038, 2020 | 35 | 2020 |
| Sequential immunization with gp140 boosts immune responses primed by modified vaccinia Ankara or DNA in HIV-uninfected South African participants G Churchyard, K Mlisana, S Karuna, AL Williamson, C Williamson, ... PloS one 11 (9), e0161753, 2016 | 24 | 2016 |
| A community-based oral public health approach to promote health equity ME Northridge, C Yu, B Chakraborty, A Port Greenblatt, J Mark, ... American journal of public health 105 (S3), S459-S465, 2015 | 24 | 2015 |
| Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial D Benkeser, DC Montefiori, AB McDermott, Y Fong, HE Janes, W Deng, ... Science translational medicine 15 (692), eade9078, 2023 | 17 | 2023 |
| Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial EG Kallas, NA Grunenberg, C Yu, B Manso, G Pantaleo, M Casapia, ... Science translational medicine 11 (519), eaaw1673, 2019 | 17 | 2019 |
| Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine D Benkeser, Y Fong, HE Janes, EJ Kelly, I Hirsch, S Sproule, AM Stanley, ... npj Vaccines 8 (1), 36, 2023 | 14 | 2023 |
| Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials Z Moodie, SR Walsh, F Laher, L Maganga, ME Herce, S Naidoo, ... PLoS medicine 17 (5), e1003117, 2020 | 8 | 2020 |
| Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 Trial Y Huang, NS Hejazi, B Blette, LN Carpp, D Benkeser, DC Montefiori, ... Viruses 15 (10), 2029, 2023 | 5 | 2023 |
| Risk of COVID-19 after natural infection or vaccination AM Rick, MB Laurens, Y Huang, C Yu, TCS Martin, CA Rodriguez, ... EBioMedicine 96, 2023 | 4 | 2023 |
| Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and … ME Sobieszczyk, S Mannheimer, CA Paez, C Yu, T Gamble, DA Theodore, ... The Lancet HIV 10 (10), e653-e662, 2023 | 2 | 2023 |
| Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial Y Fong, Y Huang, D Benkeser, LN Carpp, G Áñez, W Woo, A McGarry, ... nature communications 14 (1), 1581, 2023 | 1 | 2023 |
| First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121. 141. LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy … S Edupuganti, CB Hurt, KE Stephenson, Y Huang, CA Paez, T Gamble, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 229-229, 2022 | 1 | 2022 |
| AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period Y Huang, KE Seaton, M Casapia, L Polakowski, SC De Rosa, K Cohen, ... Vaccine 39 (33), 4641-4650, 2021 | 1 | 2021 |
| Increase in Env-specific Binding Antibody and CD4+ T Cell-responses After Month 30 Boost of gp120/MF59 Delivered Alone or With ALVAC-HIV K Cohen, M Malahleha, F Laher, LG Bekker, K Mngadi, B Daniels, ... AIDS RESEARCH AND HUMAN RETROVIRUSES 34, 90-90, 2018 | 1 | 2018 |
